Revenue Breakdown
Composition ()
No data
Revenue Streams
IQVIA Holdings Inc (IQV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Research & Development Solutions, accounting for 55.1% of total sales, equivalent to $2.26B. Other significant revenue streams include Technology & Analytics Solutions and Contract Sales & Medical Solutions. Understanding this composition is critical for investors evaluating how IQV navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, IQVIA Holdings Inc maintains a gross margin of 26.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.98%, while the net margin is 8.10%. These profitability ratios, combined with a Return on Equity (ROE) of 19.55%, provide a clear picture of how effectively IQV converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IQV competes directly with industry leaders such as ARGX and NTRA. With a market capitalization of $40.30B, it holds a significant position in the sector. When comparing efficiency, IQV's gross margin of 26.51% stands against ARGX's 90.29% and NTRA's 64.91%. Such benchmarking helps identify whether IQVIA Holdings Inc is trading at a premium or discount relative to its financial performance.
